STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Clinical trials for STAGE IIIB CUTANEOUS MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB CUTANEOUS MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIB CUTANEOUS MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple threat: new combo tackles Hard-to-Treat melanoma
Disease control OngoingThis phase II trial tests two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or can't be removed surgically. One group gets nivolumab (immunotherapy) plus trametinib and dabrafenib (targeted drugs); the other gets nivolumab plus en…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 21:01 UTC
-
Immune cocktail shows promise in Tough-to-Treat melanoma
Disease control OngoingThis phase II trial tests whether adding GM-CSF (a protein that boosts immune cell production) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be removed by surgery are randomly ass…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 12:01 UTC
-
New combo therapy for advanced melanoma enters early human testing
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and ibrutinib (Imbruvica)—in 20 people with advanced melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system attack cancer cells, while ibrutinib blocks…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Supercharged T-Cells take on melanoma in early trial
Disease control OngoingThis early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
Double immune attack: new combo therapy shows promise for tough melanoma
Disease control OngoingThis study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Major trial tests immune drug against standard therapy for High-Risk melanoma
Disease control OngoingThis large phase 3 study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. Over 1,600 patients with high-risk stage III or IV melanoma that had been completely removed took part. …
Matched conditions: STAGE IIIB CUTANEOUS MELANOMA AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC